文献速递炎症性肠病

英夫利西单抗治疗慢性活动性溃疡性结肠炎的长期结局:瑞典250例患者的多中心研究

Long-term outcome of infliximab treatment in chronic active ulcerative colitis: a Swedish multicentre study of 250 patients.
PubMed 文献 · Aliment Pharmacol Ther · 2016-12-27

该瑞典多中心回顾性研究纳入250例慢性活动性溃疡性结肠炎患者,评估英夫利西单抗长期疗效与安全性。12个月无激素临床缓解率为49.2%(123/250),中位随访2.9年时为50.4%(126/250)。3个月无应答是后续结肠切除术的独立预测因素(HR=9.40,95%CI=5.10-17.35,P<0.001)。

要点

  • 12个月无激素临床缓解率为49.2%(123/250),中位随访2.9年时为50.4%(126/250)。
  • 3个月无应答者后续结肠切除风险高,12个月时为48.3%(29/60),随访结束时为68.3%(41/60)。
  • 3个月无应答是后续结肠切除术的独立预测因素(HR=9.40,95%CI=5.10-17.35,P<0.001)。

核心结论

  • 英夫利西单抗治疗慢性活动性溃疡性结肠炎的长期疗效良好,尤其在诱导治疗应答的患者中。
  • 相反,3个月无应答预示结局不佳,后续结肠切除风险高。

研究设计与样本

  • 回顾性多中心研究,纳入250例慢性活动性溃疡性结肠炎患者接受英夫利西单抗治疗,纳入标准为年龄≥18岁、门诊治疗、激素依赖或不耐受和/或免疫调节剂难治或不耐受。

主要发现

  • 12个月无激素临床缓解率为49.2%(123/250),中位随访2.9年时为50.4%(126/250)。
  • 3个月时主要应答率为76.0%(190/250),应答者12个月应答概率为88.4%(168/190),随访时为75.3%(143/190)。
  • 主要应答者12个月结肠切除率为3.2%(6/190),末次随访时为14.2%(27/190)。
  • 3个月无应答者12个月结肠切除率为48.3%(29/60),随访时为68.3%(41/60)。
  • 12个月应答者后续结肠切除风险低于无应答者:7.7%(14/181)vs 55.9%(19/34),P<0.0001。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Real-life long-term data on infliximab treatment in ulcerative colitis are limited. AIM: To study the long-term efficacy and safety of infliximab in chronic active ulcerative colitis and possible predictors of colectomy and response were also examined. METHODS: A retrospective multi-centre study of infliximab treatment in 250 patients with chronic active ulcerative colitis with inclusion criteria: age ≥18 years, ambulatory treated, steroid-dependent or intolerant and/or immunomodulator refractory or intolerant. RESULTS: Steroid-free clinical remission was achieved by 123/250 patients (49.2%) at 12 months and in 126/250 patients at a median follow-up of 2.9 years (50.4%). Primary response at 3 months was achieved by 190/250 (76.0%) patients and associated with a high probability of response 168/190 (88.4%) at 12 months and 143/190 (75.3%) at follow-up. Long-term rate of colectomy in primary responders was 6/190 (3.2%) at 12 months and 27/190 (14.2%) at last follow-up. Failure to achieve response at 3 months was associated with a high risk of subsequent colectomy, 29/60 (48.3%) at 12 months and 41/60 (68.3%) at follow-up. Response at 12 months was associated with a low risk of subsequent colectomy, 14/181 (7.7%) compared with non-response 19/34 (55.9%) (P < 0.0001). Non-response at 3 months was an independent predictor of subsequent colectomy (HR = 9.40, 95% CI = 5.10-17.35, P < 0.001). Concomitant azathioprine therapy did not influence outcome in terms of colectomy. CONCLUSIONS: Long-term efficacy of infliximab treatment in chronic active ulcerative colitis is excellent especially in patients who respond to induction treatment. Conversely, non-response at 3 months predicts a poor outcome, with a high risk of subsequent colectomy.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Angelison L, Almer S, Eriksson A, et al. Long-term outcome of infliximab treatment in chronic active ulcerative colitis: a Swedish multicentre study of 250 patients. Aliment Pharmacol Ther. 2016. PMID: 28025840. doi:10.1111/apt.13893

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。